Early access
Sign in
Taking people in United StatesPhase 1

Studies CX11 tablets in adults with obesity or overweight

Tests CX11 tablets, compared with placebo, in adults with obesity or overweight.

Key facts

Who runs it
Corxel Pharmaceuticals
Where
Austin and Las Vegas, United StatesSee the 2 sites
Trial code
Registry title
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
Status
Recruiting
Phase
Phase 1
People taking part
90 people, planned
Started
11 May 2026
Expected to end
Jun 2027
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CX11
  • Placebo
Record updated
17 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-55 with obesity, or with overweight plus a weight-related health problem, to test the safety of CX11 tablets.

Age
18-55 years.
Sex
The registry lists females only, but the criteria text says male or female.
Disease stage
BMI ≥30.0 to ≤39.9 kg/m², or BMI ≥27.0 to <30.0 kg/m² with at least 1 of these: prediabetes, high blood pressure, dyslipidemia or obstructive sleep apnea.
Earlier treatment
A previous diet or exercise weight-loss attempt that did not work, and stable body weight within 90 days. Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery or device, or investigational treatment are not allowed.

Main reasons for not taking part

  • Diabetes, or obesity caused by hormone or genetic conditions
  • Recent weight-loss drugs, GLP-1-based therapy or obesity surgery
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia
  • Pregnancy or breastfeeding
  • Significant heart, liver, kidney, thyroid, stomach and gut, or mental health problems

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Male or female, 18-55 years
  • BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to <30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea
  • Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days
  • Able to comply with study procedures and reproductive requirements

Who cannot take part

  • Diabetes or obesity due to endocrine/genetic causes
  • Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia
  • Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate
  • Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment
  • Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United States

  • Austin, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Las Vegas, NevadaHospital not named in the registryContact: Study DirectorTaking people

About the trial

What the trial wants to find out

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

The 4 groups in the trial

  • Placebo groupPlacebo, for comparison

    Placebo

    Treatment: Placebo

  • CX11 Group ATreatment being tested

    Treatment: CX11

  • CX11 Group BTreatment being tested

    Treatment: CX11

  • CX11 Group CTreatment being tested

    Treatment: CX11

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities
Plain-language title
Studies CX11 tablets in adults with obesity or overweightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07652047, who can take part
Record updated
17 June 2026